<DOC>
	<DOCNO>NCT01459445</DOCNO>
	<brief_summary>The purpose study assess effect ethinylestradiol 30µg-drospirenone combined metformin weight loss mean dietary intervention index endothelial dysfunction ( i.e . flow-mediated dilation serum endothelin-1 ) , serum hsCRP , lipid , insulin resistance body composition young woman PCOS .</brief_summary>
	<brief_title>Metformin+ Drospirenone/ethinylestradiol30µg Flow-mediated Dilation Polycystic Ovary Syndrome</brief_title>
	<detailed_description>Women polycystic ovary syndrome ( PCOS ) frequently cluster several cardiovascular risk marker early subclinical atherosclerosis . Because combined oral contraceptive ( COCs ) , common treatment disease , might adversely influence insulin resistance , glucose tolerance , lipid profile aggravate chronic inflammation possibility worsen already unfavorable cardiovascular risk profile PCOS subject concern . On contrary , insulin sensitizer metformin show ameliorate insulin resistance , reduce hyperandrogenism triglyceride level also improve endothelial structure function PCOS . Drospirenone ( DRP ) progestin antiandrogenic antimineralocorticoid activity . However , study assess effect COC contain 30 µg EE+3mg DRP ( DRP/EE30µg ) surrogate marker atherosclerosis inconclusive . Therefore , purpose present study assess effect oral contraceptive DRP/EE30µg combine metformin weight loss mean dietary intervention index endothelial dysfunction , i.e . flow-mediated dilation serum endothelin-1 , serum hsCRP , lipid , insulin resistance young woman PCOS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>woman diagnosis polycystic ovary syndrome define accord Androgen Excess Society 2006 guideline secondary cause hyperandrogenism hyperprolactinemia , thyroid disease , androgensecreting tumour , Cushing 's syndrome congenital adrenal hyperplasia current previous use ( within 6 month ) oral contraceptive , antiandrogens , ovulation induction medication use drug know affect carbohydratelipid metabolism inflammation ( antiinflammatory drug ) time evaluation last one month precede evaluation concurrent minor infection report last one month precede evaluation personal history diabetes mellitus</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ethinylestradiol 30µg-drospirenone</keyword>
	<keyword>flow-mediated dilatation</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>hsCRP</keyword>
	<keyword>metformin</keyword>
	<keyword>polycystic ovary syndrome</keyword>
</DOC>